Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Sky One Has Another 26 Products Awaiting Approval

publication date: Sep 10, 2008

China Sky One Medical, with its near-constant barrage of press releases, sometimes seems like an overactive child who always demands attention. On the other hand, the company’s insistent press release schedule is understandable because the company is growing rapidly, its finances are in good order, but investors don’t seem to be paying attention. Today, the company announced that its Heilongjiang Tianlong Pharmaceutical subsidiary has completed its R&D on 26 new drugs and submitted the drugs to the SFDA for approval. More details...

Stock Symbol: (AMEX: CSY)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here